Polyzois Makras1,2, Athanasios D Anastasilakis3,4, George Antypas3,5, Efstathios Chronopoulos3,6, Evangelia G Kaskani3,7, Aikaterini Matsouka3, Dimos K Patrikos3,8, Konstantinos D Stathopoulos3,9, Symeon Tournis3,10, George Trovas10, Christos Kosmidis3,11. 1. Department of Endocrinology and Diabetes and Department of Medical Research, 251 Hellenic Air Force General Hospital, 3 Kanellopoulou St., 115 25, Goudi, Athens, Greece. pmakras@gmail.com. 2. Hellenic Society for the Study of Bone Metabolism, Athens, Greece. pmakras@gmail.com. 3. Hellenic Society for the Study of Bone Metabolism, Athens, Greece. 4. Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece. 5. Department of Orthopedics, "St. Panteleimon" General Hospital of Nikaia, Piraeus, Greece. 6. 2nd University Orthopaedic Department, Athens Medical School, National and Kapodistrian University, Athens, Greece. 7. 1st Health Division of Attica, Chalandri Health Centre Athens, Chalandri, Greece. 8. "Metropolitan" General Hospital, Piraeus, Greece. 9. Post-Graduate Course on Bone Metabolic Diseases, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. 10. Laboratory for Research of the Musculoskeletal System "Th. Garofalidis", Medical School, KAT Hospital, National and Kapodistrian University of Athens, Athens, Greece. 11. 1st Health District of Attica, Alexandras Health Centre, Athens, Greece.
Abstract
We report the updated guidelines for the management of osteoporosis in Greece, which include guidance on fracture risk assessment, diagnosis-pharmacological treatment-follow-up of osteoporosis based on updated information, and national evidence from Greek clinical practice and the healthcare setting. PURPOSE: The purpose of this report was to update the Guidelines for the Management of Osteoporosis in Greece that was published in 2011. METHODS: In line with the GRADE system, the working group initially defined the main clinical questions that should be addressed when dealing with the diagnosis and management of osteoporosis in clinical practice in Greece. Following a literature review and discussion on the experience gained from the implementation of the 2011 Guidelines transmitted through the national electronic prescription network, the Hellenic Society for the Study of Bone Metabolism (HSSBM) uploaded an initial draft for an open dialogue with the relevant registered medical societies and associations on the electronic platform of the Greek Ministry of Health. After revisions, the Central Health Council approved the final document. RESULTS: The 2018 Guidelines provide comprehensive recommendations on the issues of the timing of fracture risk evaluation and dual-energy X-ray absorptiometry (DXA) measurement, interpretation of the DXA results, the diagnostic work-up for osteoporosis, the timing as well as the suggested medications for osteoporosis treatment, and the follow-up methodology employed during osteoporosis treatment. CONCLUSIONS: These updated guidelines were designed to offer valid guidance on fracture risk assessment, diagnosis-pharmacological treatment-follow-up of osteoporosis based on updated information and national evidence from clinical practice and the healthcare setting. Clinical judgment is essential in the management of every individual patient for the purpose of achieving the optimal outcome in the safest possible way.
We report the updated guidelines for the management of osteoporosis in Greece, which include guidance on fracture risk assessment, diagnosis-pharmacological treatment-follow-up of osteoporosis based on updated information, and national evidence from Greek clinical practice and the healthcare setting. PURPOSE: The purpose of this report was to update the Guidelines for the Management of Osteoporosis in Greece that was published in 2011. METHODS: In line with the GRADE system, the working group initially defined the main clinical questions that should be addressed when dealing with the diagnosis and management of osteoporosis in clinical practice in Greece. Following a literature review and discussion on the experience gained from the implementation of the 2011 Guidelines transmitted through the national electronic prescription network, the Hellenic Society for the Study of Bone Metabolism (HSSBM) uploaded an initial draft for an open dialogue with the relevant registered medical societies and associations on the electronic platform of the Greek Ministry of Health. After revisions, the Central Health Council approved the final document. RESULTS: The 2018 Guidelines provide comprehensive recommendations on the issues of the timing of fracture risk evaluation and dual-energy X-ray absorptiometry (DXA) measurement, interpretation of the DXA results, the diagnostic work-up for osteoporosis, the timing as well as the suggested medications for osteoporosis treatment, and the follow-up methodology employed during osteoporosis treatment. CONCLUSIONS: These updated guidelines were designed to offer valid guidance on fracture risk assessment, diagnosis-pharmacological treatment-follow-up of osteoporosis based on updated information and national evidence from clinical practice and the healthcare setting. Clinical judgment is essential in the management of every individual patient for the purpose of achieving the optimal outcome in the safest possible way.
Authors: Polyzois Makras; Panagiotis Petrikkos; Athanasios D Anastasilakis; Artemis Kolynou; Angeliki Katsarou; Olga Tsachouridou; Symeon Metallidis; Maria P Yavropoulou Journal: Bone Rep Date: 2021-09-10
Authors: Timothy J S Chesser; Muhammad Kassim Javaid; Zaineb Mohsin; Carlotta Pari; Alberto Belluati; Achille Contini; Vincenzo Caiaffa; Francisco Chana-Rodríguez; Jesus Gómez-Vallejo; Coral Sánchez-Pérez; Zoe H Dailiana; Nikolaos Stefanou; Theodoros Tosounidis; Michaël Laurent; Guy Putzeys; Martijn Poeze; Kees Jan Ponsen Journal: OTA Int Date: 2022-06-09